Publication of List of Manufacturers Suspended from Licensing for the Manufacture of Therapeutic Goods Under Section 41

Overview

The Therapeutic Goods Act 1989, enacted by the Commonwealth of Australia Parliament, serves to regulate the safety, quality, and efficacy of therapeutic goods available in Australia. The Act addresses the critical need to ensure that therapeutic goods, including medicines, medical devices, and blood products, meet stringent standards to protect public health. This legislation empowers the Therapeutic Goods Administration to monitor and control the manufacturing, importation, advertising, and distribution of therapeutic goods. The policy objective of the Act is to maintain and enhance the health and safety of the Australian population by ensuring that only safe, high-quality therapeutic goods are available on the market. The publication of the suspension of a manufacturer's licence, as seen in the Gazette notice of 2017, exemplifies the Act's role in enforcing compliance and maintaining the integrity of the therapeutic goods supply chain.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration (TGA), applies to the regulation of therapeutic goods within Australia. This includes overseeing the quality, safety, and efficacy of therapeutic goods such as medicines, medical devices, blood and blood components, tissues, and vaccines. The Act applies to a wide range of entities including manufacturers, importers, and suppliers of therapeutic goods. It imposes obligations on these entities to ensure their goods meet specific standards and are appropriately licensed. The Act's jurisdictional reach extends across the Commonwealth of Australia, ensuring a unified regulatory framework. Notably, the Act does not apply to goods regulated under other federal legislation, such as blood and blood products regulated under the National Health and Medical Research Council Act 1992. The Act provides for the suspension of manufacturing licenses where there are concerns about the quality or safety of the therapeutic goods produced, as evidenced by the notice issued under Section 41(1)(d) concerning the Royal Adelaide Hospital Radiopharmacy. This suspension is a specific enforcement measure that can be implemented to protect public health, and it operates within the broader legislative framework that may be further defined or extended through subordinate instruments and regulations.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) includes provisions for the regulation of therapeutic goods in Australia. Section 41(1)(d) of the Act specifically empowers the Secretary to suspend a manufacturer's licence under certain circumstances. In this instance, the Secretary has exercised this power by issuing a written notice suspending the licence held by Royal Adelaide Hospital Radiopharmacy, with Licence Number MI-12112004-LI-000163-1. The suspension has been requested by the manufacturer themselves and will remain in effect from 1 January 2017 to 31 December 2017. The obligations and requirements imposed by the Act on the parties involved are primarily focused on ensuring the quality, safety, and efficacy of therapeutic goods. Manufacturers must adhere to stringent standards to maintain their licences and must promptly report any issues that could affect the safety or quality of their products. In this case, the manufacturer of the therapeutic goods has taken the proactive step of requesting the suspension of their licence, which demonstrates their commitment to ensuring compliance with the Act’s stringent requirements. The Act also requires manufacturers to maintain thorough records and to cooperate with any inspections or investigations conducted by the Therapeutic Goods Administration. Failure to comply with the Act’s provisions can result in severe consequences. The Act provides for both civil and criminal penalties for breaches. Civil penalties may include fines, while criminal penalties can include imprisonment. Specifically, under Section 26 of the Act, a person who contravenes certain provisions can be liable to a fine of up to 5,000 penalty units for an individual and up to 50,000 penalty units for a body corporate. Additionally, under Section 30, a person who is found guilty of an offence against the Act can be imprisoned for up to five years. These penalties underscore the seriousness with which the Act treats breaches of its provisions and the importance of strict adherence to the regulatory framework it establishes.